GenFit operates in a rare position for a biotech company by fully funding its three Phase 2 programs through royalty streams from a partnership with Ipsen and revenue from its commercialized MASH diagnostic. This model avoids shareholder dilution and reduces financial risk, providing significant operational stability.
The MASH market's potential can only be unlocked by a scalable, non-invasive diagnostic. Biopsies are not feasible for a 90-million-person potential market. Diagnostics are essential for identifying patients and monitoring the efficacy of expensive new treatments, a key requirement for all stakeholders.
GenFit's CEO reveals a fluid capital markets strategy. The company delisted from US exchanges due to high costs and low news flow but is now considering a return as its pipeline advances. This demonstrates that a public listing is viewed as a strategic option to be utilized when conditions are optimal, not a permanent necessity.
The MASH diagnostic's value extends beyond clinical utility. It serves the needs of multiple stakeholders: payers avoid wasting money, drug manufacturers ensure their products reach the right patients, and prescribers make data-driven decisions. This multi-stakeholder alignment is key to its adoption.
